CASE REPORTS
Add like
Add dislike
Add to saved papers

Kikuchi-Fujimoto disease following vaccination against COVID-19.

The purpose of this study is to explore the clinicopathological features of Kikuchi-Fujimoto disease (KFD) following vaccination against coronavirus disease 2019 (COVID-19). One case of KFD following vaccination against COVID-19 was examined clinically, histologically, and immunohistochemically. The patient was a 36-year-old Chinese man who suffered from fever and cervical lymph node swelling following simultaneous administration of the COVID-19 vaccine. The patient was diagnosed with KFD based on the histopathological findings of a lymph node core needle biopsy, and his fever and swelling resolved 2 months later without therapy. Although the exact pathogenesis of the development of KFD following immunization remains unknown, this information should be added to the list of potential triggers or factors associated with the development of KFD.

Full text links

Management of Latent Tuberculosis Infection.JAMA 2023 January 20
Misdiagnosis in the Emergency Department: Time for a System Solution.JAMA 2023 January 28

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app